Zobrazit v EDS

Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas

Uloženo v:
Podrobná bibliografie
Název: Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas
Autoři: Dhayat, Sameer A., Yang, Zixuan
Zdroj: J Cancer Res Clin Oncol
Informace o vydavateli: Springer Science and Business Media LLC, 2020.
Rok vydání: 2020
Témata: 0301 basic medicine, Digital droplet PCR, Circulating Tumor DNA [MeSH], Pancreatic Neoplasms/diagnosis [MeSH], Next-generation sequencing, Biomarkers, Tumor [MeSH], DNA, Neoplasm [MeSH], Genetic Variation [MeSH], Liver Neoplasms/genetics [MeSH], Pancreatic cancer, Carcinoma, Hepatocellular/blood [MeSH], Pancreatic Neoplasms/genetics [MeSH], Liver Neoplasms/diagnosis [MeSH], Humans [MeSH], Hepatocellular carcinoma, Liquid Biopsy [MeSH], Carcinoma, Hepatocellular/diagnosis [MeSH], Genomics/methods [MeSH], Circulating tumor DNA, Carcinoma, Hepatocellular/genetics [MeSH], Liver Neoplasms/blood [MeSH], DNA Methylation [MeSH], Review – Cancer Research, Prognosis [MeSH], Pancreatic Neoplasms/blood [MeSH], High-Throughput Nucleotide Sequencing [MeSH], Carcinoma, Hepatocellular, Liver Neoplasms, Liquid Biopsy, Genetic Variation, High-Throughput Nucleotide Sequencing, DNA, Neoplasm, Genomics, DNA Methylation, Prognosis, Circulating Tumor DNA, 3. Good health, Pancreatic Neoplasms, 03 medical and health sciences, 0302 clinical medicine, Biomarkers, Tumor, Humans
Popis: Hepatocellular carcinoma (HCC) and pancreatic cancer (PC) belong to the most lethal malignancies worldwide. Despite advances in surgical techniques and perioperative multidisciplinary management, the prognosis of both carcinoma entities remains poor mainly because of rapid tumor progression and early dissemination with diagnosis in advanced tumor stages with poor sensitivity to current therapy regimens. Both highly heterogeneous visceral carcinomas exhibit unique somatic alterations, but share common driver genes and mutations as well. Recently, circulating tumor DNA (ctDNA) could be identified as a liquid biopsy tool with huge potential as non-invasive biomarker in early diagnosis and prognosis. CtDNA released from necrotic or apoptotic cells of primary tumors, metastasis, and circulating tumor cells can reveal genetic and epigenetic alterations with tumor-specific and individual mutation and methylation profiles. In this article, we focus on clinical impact of ctDNA as potential biomarker in patients with HCC and PC.
Druh dokumentu: Article
Other literature type
Jazyk: English
ISSN: 1432-1335
0171-5216
DOI: 10.1007/s00432-020-03219-5
Přístupová URL adresa: https://link.springer.com/content/pdf/10.1007/s00432-020-03219-5.pdf
https://pubmed.ncbi.nlm.nih.gov/32338295
https://link.springer.com/content/pdf/10.1007/s00432-020-03219-5.pdf
https://link.springer.com/article/10.1007/s00432-020-03219-5
https://pubmed.ncbi.nlm.nih.gov/32338295/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256092
https://repository.publisso.de/resource/frl:6467704
Rights: CC BY
Přístupové číslo: edsair.doi.dedup.....35ccff7fc9fe7bdebbce408398809c10
Databáze: OpenAIRE
Popis
Abstrakt:Hepatocellular carcinoma (HCC) and pancreatic cancer (PC) belong to the most lethal malignancies worldwide. Despite advances in surgical techniques and perioperative multidisciplinary management, the prognosis of both carcinoma entities remains poor mainly because of rapid tumor progression and early dissemination with diagnosis in advanced tumor stages with poor sensitivity to current therapy regimens. Both highly heterogeneous visceral carcinomas exhibit unique somatic alterations, but share common driver genes and mutations as well. Recently, circulating tumor DNA (ctDNA) could be identified as a liquid biopsy tool with huge potential as non-invasive biomarker in early diagnosis and prognosis. CtDNA released from necrotic or apoptotic cells of primary tumors, metastasis, and circulating tumor cells can reveal genetic and epigenetic alterations with tumor-specific and individual mutation and methylation profiles. In this article, we focus on clinical impact of ctDNA as potential biomarker in patients with HCC and PC.
ISSN:14321335
01715216
DOI:10.1007/s00432-020-03219-5